The Evolving Paradigm of Antibody–Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases is a research paper published in Pharmaceutics (2024). On theSindex it has a DataRank of 0. It has been cited 14 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI
Grant: R01 CA226894
NCI
Grant: R21 CA270716
NCI
Grant: R21CA282378
NCI
Grant: RP210092
NCI
Grant: RP210045
NCI
Grant: T32 GM139801
National Institutes of Health
Grant: 1R21CA282378-01A1
Bispecific drug-conjugates for treating colorectal cancer
National Institutes of Health
Grant: 5R01CA226894-03
Mechanisms and therapeutic targeting of colon cancer stem cell plasticity
National Institutes of Health
Grant: 5T32GM139801-02
Training Interdisciplinary Pharmacology Scientists (TIPS)
National Institutes of Health
Grant: 1R21CA270716-01
Novel Antibody-Drug Conjugate Combination Therapy for Treating Colorectal Cancer
FWCI
2.56
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals